Pulse Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on May 4, 2023. The report discloses amendments to the employment agreements of the Company's Chief Executive Officer, Kevin Danahy, and Chief Technology Officer, Darrin Uecker.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
The Board of Directors approved changes to the compensation structure for two executive officers effective May 4, 2023, and May 5, 2023:
- Base Salary: Increased from $400,000 to $450,000 per year for both executives.
- Cash Bonus Target: Reduced from 100% to 88.88% of base salary for both executives.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the specific compensation changes.
Investor Verification Checklist
- Verify the total annual compensation cost impact of the salary increase versus the bonus target reduction.
- Review the full text of Exhibits 10.1 and 10.2 for additional terms, vesting schedules, or severance provisions not detailed in the summary.
- Confirm if these changes align with the Company's broader cost-management or retention strategies.